Stockscreener 앱 받기
4.46
4.70%
-0.22
전일 마감가:
$4.68
열려 있는:
$4.68
하루 거래량:
260.30K
Relative Volume:
0.49
시가총액:
$254.26M
수익:
$7.15M
순이익/손실:
$-20.60M
주가수익비율:
9.3974
EPS:
0.4746
순현금흐름:
$-97.99M
1주 성능:
-6.30%
1개월 성능:
+17.06%
6개월 성능:
+56.49%
1년 성능:
+175.31%
1일 변동 폭
$4.41
$4.68
1주일 범위
$4.22
$4.89
52주 변동 폭
$1.57
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
명칭
Whitehawk Therapeutics Inc
전화
551-321-2234
주소
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
4.46 | 268.51M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | Oppenheimer | Outperform |
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - TradingView
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView
Whitehawk Therapeutics reports $16.6 million Q2 loss as trials advance - quiverquant.com
Whitehawk Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Whitehawk Therapeutics 2Q Loss/Shr 20c >WHWK - Moomoo
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and ResistanceWave Extension - dars.gov.et
Akari Therapeutics Highlights WhiteHawk Collaboration and Dual-Payload ADC Strategy in CEO Corner Segment - quiverquant.com
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Yahoo Finance
Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
Whitehawk Therapeutics Inc (WHWK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WHWK|WHWK|Price:3.940|Chg%:+0.090 - tradingkey.com
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
WHWK|WHWK|Price:3.710|Chg%:-0.120 - TradingKey
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Akari Therapeutics Collaborates with Whitehawk Therapeutics to Expand ADC Payload Platform Potential - Barchart.com
WHWK|Price:3.710|Chg%:-0.120 - TradingKey
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - GlobeNewswire
Akari and Whitehawk collaborate on ADC research - BioWorld News
Akari Therapeutics Announces Strategic Preclinical Research Collaboration with Whitehawk Therapeutics on Dual-Payload ADC Development - Quiver Quantitative
Akari and Whitehawk to Test Two ADC Payloads in Preclinical Studies - Stock Titan
Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News - Moomoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - Yahoo Finance
How Low Will Whitehawk (WHWK) Go After -2.57% Sell-Off? 2026-07-20Sector Leader Stocks - po-news-eg.net
Whitehawk Therapeutics (WHWK) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest - MarketBeat
WHWK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350 - TradingView
Leerink Partners Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $9 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
WHWK Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Gain on Cost ControlEarnings Cycle Outlook - dars.gov.et
Biocytogen and Whitehawk partner to develop ADCs - Yahoo Finance
Whitehawk Therapeutics (WHWK) Q4 2024 earnings summary - Quartr
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development - marketscreener.com
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Upturn
Whitehawk Therapeutics (WHWK) Slips 4% as Stock Tests Key Support LevelsMid Cap Momentum - dars.gov.et
WHWKWhitehawk Therapeutics Inc Options - Finviz
Whitehawk Therapeutics (WHWK) Gains 6.1% as Biotech Sector Momentum BuildsVolatility Term Structure - dars.gov.et
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Index - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Value Benchmark - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Price to sales forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Whitehawk Therapeutics Inc (WHWK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):